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Increased Circulating Concentrations of Interleukin 2 Receptor during Rejection Episodes in
Heart- or Kidney-Transplant Recipients
GlanCarloZucchelll,’ AldoClerlco,’Renata De Maria,3MarioCarmeIllnl,2 Rossella Dl Stefano,2SllvanoMasIni,’
Alessandro Pile,’ and Lulgl Donato’
Concentrations of interleukin 2 receptor (slL-2R) have been
suggested as a marker of rejection episodes after organ
transplantation. To evaluate the analytical performance of a
“sandwich-type” enzyme immunoassay method for sIL-2R
and to verify whether increased concentrations of sIL-2R
might be a useful marker of allograft rejection, we quantified
sIL-2R in serum samples from heart- or kidney-transplant
patients. The mean (±SD) pre-transplant value of slL-2R
(592 ± 209 kiio-units/L) in heart-transplant patients was
significantly higher (P <0.01) than that observed in controls
(350 ± 101 kilo-units/L). After heart transplantation, the
concentrations of siL-2R slowly decreased to baseline in
successfully treated patients but increased significantly
(1129 ± 215 kilo-units/L; P <0.01) during acute rejection
crisis. However, severe infections were also associated with
a significant increase of sIL-2R, so the sIL-2R test is not
specific for allograft rejection. The mean pre-transpiant con-
centration of slL-2R was also increased (1943 ± 878 kilo-
units/L) in 26 renal-transplant patients; after transplantation,
this value returned to normal, as did that for creatinine, but
persisted steadily high in five patients who experienced acute
tubular necrosis. In this group of patients, the slL-2R con-
centration increased by 1.5- to fourfold, both during acute
rejection episodes and in clinically evident infection; thus
measurement of creatinine and siL-2R concentrations can
help to distinguish between rejection, infection, and cyclo-
sporine toxicity. In two episodes of mild cyclosponne-induced
nephrotoxicity, we observed slight increases in serum creat-
mine (which returned to baseline when the cyclosporine dose
was decreased) not associated with an increase in slL-2R.
We conclude that systematic monitoring of slL-2R together
with other biochemical and clinical markers may be useful in
the management of kidney-transplant patients.
Additional Keyphrases: creatinine cyclosporine - nephro-
toxicity
Interleukin 2 (IL-2), a T-cell growth factor, is synthesized
and secreted after activation with antigen or mitogen in
the presence of the monokine interleukin 1 (1, 2). The
activation of T-lymphocytes is accompanied by expression
of specific high-affinity membrane receptors for IL-2 (IL-
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2R) and release into extracellular fluids of immunoassay-
detectable amounts of IL-2R (soluble IL-2R or sIL-2R) (3,
4). The sIL-2R glycoprotein has a peptide backbone that is
smaller than that of its membrane-associated counterpart
(45 000 vs 55 000 Da) and also binds IL-2 (4, 5), although
with lower affinity(6).
Increased circulating concentrations of sIL-2R are detect-
able in several conditions, e.g., hematological neoplasia (7,
8), viral infections (7), and granulomatous disorders (9,10).
Some have also suggested that the concentrations of serum
sIL-2R deriving from activated cell turnover may indicate
rejection or infection during organ transplantation (11-13).
Colvin et al. (11) suggested that sIL-2R assay may be useful
clinically in the differential diagnosis of renal allograft
rejection, especially in distinguishing cyclosporine (CsA)
nephrotoxicity; in fact, in kidney-transplant recipients,
sIL-2R greatly increased during rejection or viral infec-
tions, whereas patients with CsA nephrotoxicity had
sIL-2R concentrations significantly below those of patients
with rejection (11). Moreover, two preliminary reports
suggest that an increase of sIL-2R in heart-, heart-lung-, or
liver-transplant recipients may be associated with a worse
prognosis (12) and that the determination of sJL-2R con-
centrations may prove useful in monitoring cardiac al-
lograft rejection (13).
To evaluate the analytical performances of a “sandwich-
type” enzyme immunoassay method for measuring sIL-2R
and to veriI’ whether increased concentrations of circulat-
ing sIL-2R may be considered a useful marker of allograft
rejection, we assayed sIL-2R concentrations in serum sam-
ples of heart- or kidney-transplant patients.
Materials and Methods
sJL-2R assay. The sIL-2R concentration was assayed by a
sandwich enzyme immunoassay method (T Cell Science,
Inc., Cambridge, MA 02139) that involves two different
anti-IL-2R monoclonal antibodies; the firstone is adsorbed
onto polystyrene microtiter wells and the other is conju-
gated with horseradish peroxidase (EC 1.11.1.7). Soluble
IL-2R present in the serum sample binds to antibody on the
well and, after washing of the unreacted materials, the
enzyme conjugated to the anti-IL-2R antibody is added to
complete the sandwich. The unbound enzyme-conjugated
antibody is then removed and a substrate solution (hydro-
gen peroxide/o-phenylenediamine) is added to form a col-
ored product (measured at 490 nm), the quantity of which
is proportional to the amount of sIL-2R present in the
sample. The concentration of unknown samples is esti-
mated by interpolation on a calibration curve prepared
with five sIL-2R standards. sIL-2R concentration is ex-
pressed in kilo-units per liter, 1 kilo-unit being defined as
the amount of sIL-2R released or present in 1 mL of a
standardpreparation of cell-culture supernatant fluid from sensitivity (lowest detection limit) was 53 ± 20 kilo-
phytohemagglutinin-stimulated peripheral blood cells (T urnts/L. The between-assay variability (CV), as assessed by
Cell Science, Inc.).
The mean precision profile was cumulatively computed
measuring (in eight runs) three serum pools containing
different amounts of sIL-2R (349 ± 37, 628 ± 66, or 989 ±
from 10 assays, by use of a previously described computer
program (14, 15); the sensitivity (lowest detection limit)
was read on the precision proffle as the lowest concentra-
tion distinguishable from zero (confidence limit ±2 SD) or
the concentration corresponding to a CV of 50%; the work-
ing range, also derived from the precision proffle, was the
concentration range measurable with a within-assay pre-
cision (CV) <10%. The concentration of CsA in blood
samples was measured by fluorescence polarization immu-
noassay (TDx; Abbott Labs., N. Chicago, IL), as previously
reported(16).
Healthy subjects. We studied 38 adult blood donors (26
men and 12 women, ages 18-60 years).
Heart failure and transplantation. We studied 13 heart-
transplant patients: six who developed a biopsy-proven
episode of acute rejection that was successfully treated with
supplementary immunosuppression, five with a severe
nonviral infection, and two others with acute viral infec-
tions. All these patients were receiving standard therapy
with CsA and steroids. A baseline value for sIL-2R was
established for each patient in a clinically and instrumen-
tally determined rejection-free and infection-free interval,
These heart rejection episodes were graded histologically
as moderate, according to Billingham (17). The patients
underwent routine endomyocardial biopsy weekly in the
firstmonth, every two weeks for the second and third
month, once every month thereafter until the sixthmonth,
and whenever clinically indicated. Supplementary treat-
ment with pulsatile steroids (1 g of methylprednisolone
intravenously or 100 mg of oral prednisone for three days)
was administered for moderate rejection or mild rejection
plus clinical finding of heart failure. Persistent rejection
afterthis therapy with steroids was treatedwith horse
anti-lymphocyte globulin (20 mg/kg of body wt, intrave-
nously, for 10 days).
Kidney end-stage disease and transplantation. We stud-
ied 39 patients (27 men and 12 women, ages 32-76 years)
with end-stage renal disease who had been treated by
hemodialysis for from six months to 22 years; 35% of them
102 kilo-units/L) was 10.7%, 10.5%, and 10.3%, respec-
tively. Serial sample dilution (parallelism test) showed a
linear relationship (r = 0.999) with dilution.
Control subjects. The mean (± SD) sIL-2R concentration
in 38 healthy subjects was 350 ± 101 kilo-unitsfL (range
165-630 kilo-unitsfL), without any significant difference
between men and women.
Heart -transplant patients. The mean pre-operative value
of sIL-2R (592 ± 209 kilo-unitsfL)found in 13 heart-
transplant patients was significantly (P <0.01) higher than
that observed in controls. In six transplant patients, sIL-2R
increased significantly over the baseline values (1129 ±
215 kilo-unitsfL, P <0.01 by paired t-test) during acute
rejection crisis documented by clinical findings and myo-
cardial biopsy; these increases were significantly reduced
baseline aftersuccessful treatment (544 ± 395 kilo-
units/Li, p <0.01). Moreover, we observed that severe bac-
terial (n = 5) or viral (n = 2) infections were also accom-
panied by a significant increase of sIL-2R concentrations in
serum (1076 ± 263 vs 486 ± 146 kilo-units/L, P <0.01, in
bacterial infections; 1290 ± 368 vs 370 ± 85 kilo-unitsfL in
viral infections).
Patients with end-stage renal disease or renal transpian-
tation. sIL-2R concentrations were increased both before
(1829 ± 797 kilo-unitsfL)and afterhemodialysis (1846 ±
805 kilo-units/L)in 39 patients with end-stage renal dis-
ease;there were no significant differences between mem-
branes, length of dialysis, and type of primary renal dis-
ease. The mean (± SD) pre-operation concentration of
sIL-2R was also increased (1943 ± 878 kilo-units/L) in the
patients who received a renal transplant; after transplan-
tation, the sIL-2R decreasedto normal values, following
the pattern of creatinine concentrations. The rate of de-
crease varied in all uneventful transplants but values
stayed high in five patients who experienced acute tubular
necrosis requiring dialysis for the firstweek or so after
transplantation. Figure 1 shows a typicaltime-course for
the concentrations of sIL-2R and serum creatinine in one
were undergoing hemodialysis with cuprophan dialyzers,
65% with polyacrylonitrile.
Finally, we monitored for 15 months a group of 26 5001200
patients (ages 18-59 years) who underwent renal trans-
plantation. All these patients were on standard triple
immunosuppressive therapy: azathioprine, low-dose CsA (8
mg/kg of body wt daily), and steroids. The dose of CsA
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administered was determined aftermonitoring the circa-
lating concentrations of the drug (target range 300-600
gfL). Biopsy-proven rejection episodes were treated with
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steroids (methylprednisolone, 500 mg/day, for three to five
days) and, if the patient did not respond, with OKT3
monoclonal antibody (5 mg/day for 14 days). The clinical
diagnosis of acute CsA nephrotoxicity was made when the
renal function, as reflected by the concentration of serum
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creatinine, improved with a decrease of CsA dose.
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Analytical performances of the sIL-2R assay. The dose-
response curve of the sIL-2R assay was approximately
linear in the range 100-1600 kilo-unitsfL; the working
range extended from 250 to 1600 kilo-unitsfL; the mean
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Fig. 1. Typical time-courseof the concentrationof sIL-2R and
serum creatinine in a patient with uneventful kidney transplant
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Table 1. Serum Concentrations of Creatinine and
siL-2R and Blood CsA Concentrations in a Renal-
Transplant Recipient with Mild CSA Nephrotoxicity
Day after Serum creatlnine, Bleed CsA, IL-2R,
transplantation pmoliL jig/L kilo-units/I.
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patient with uneventful kidney transplant. The difference
in decay rate of sIL-2R after renal transplant was indepen-
dent of the type of allograft. In addition, high pro-operation
concentrations of sIL-2R did not correlate with immunolog-
ical post-transplant events and did not predict subsequent
allograft loss.
Eight kidney-transplant patients had 11 rejection epi-
sodes (documented by biopsy) that were reversed by OKT3
treatment. The concentration of IL-2R at the beginning of
acute rejection showed a 1.5- to fourfold increase. More-
over, we observed that in five infection episodes (including
two cases of interstitial pneumonias) sIL-2R was increased
up to sixfold. Figure 2 shows the time-course of sIL-2R in a
patient who experienced an episode of acute rejection
(reversed by treatment) and two episodes of viral infection.
During the rejection episode, the concentrations of sIL-2R
and creatinine simultaneously increased, whereas the in-
fections produced an increase of sIL-2R only, with no
change of serum creatiine.
Two episodes of mild CsA nephrotoxicity were observed;
in these patients only a slight increment of serum creati-
nine (which returned to baseline when the CsA dose was
decreased) was found, whereas the sIL-2R was unaffected.
Table 1 reports concentrations of CsA, sIL-2R, and creati-
nine in one of these two patients.
Discussion
We found the enzyme imniunoassay technique used in
the present study to be suitable and reliable for the mea-
surement of sIL-2R concentration in transplant patients.
Our results indicate that sIL-2R concentrations increase to
the same extent both during allograft rejection and infec-
tion episodes in heart- or kidney-transplant patients; there-
fore, the sIL-2R test is nonspecific and cannot distinguish
rejection from infection. However, in renal transplant,
rejection produces a characteristic pattern, i.e., a parallel
increase in both creatinine and sIL-2R. Moreover, we were
able to observe in these patients two episodes of mild CsA
nephrotoxicity in which creatimne (and CsA) increased
while sJL-2R remained steady. These data confirm the
Fig. 2. Time-courseof sIL-2R and creatinineconcentrationsin a
kidney-transplantpatientwithone episodeof allograftrejectionand
two episodesof viral infections
Note the simultaneous increase of slL-2R and creatinine during the rejection
episode,whereasduring infectionsonly sIL.2R increasedwith no change in
serumcreatinine concentrations
5 106 537 940
8 97 550 800
21 115 1137 740
40 97 535 450
80 88 382 380
CsA nephrotoxicityepisode documented by the slight increase in serum
creatinineconcomitantlywith a doublingof the CsA bloodconcentration.Two
to three weeksafter, when theCsA dose was decreased, the concentrations
of CsA and creatininereturnedtotheir normalranges. The concentrationsf
sIL-2R declinedprogressivelyand continuously throughoutthis period,reach-
ing the normal rangeone month after transplantation.
findings of Colvin et al. (11), who suggested that sIL-2R
measurement may be useful in distinguishing between
CsA nephrotoxicity, rejection, and viral infection. In the
rejection episodes, however, the concomitant increase of
sIL-2R and creatinine suggest that the sIL-2R test is not
more sensitive than the creatinine assay.
We conclude that systematic monitoring of sIL-2R as
well as other biochemical and clinical markers can be a
useful tool in managing kidney-transplant patients.
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Insufficient Accuracy and Specificity of Polyanion Precipitation Methods for Quantifying
Low-Density Lipoproteins
RUdigerSlekmeier,WinfrledM#{228}rz,and WernerGroB1
Recently, polyanion precipitation assays for low-density lipo-
protein (LDL)-cholesterol have been found to underestimate
their analyte in normolipidemic samples (Siekmeier et al.,
Clin Chim Acta 1988;177:221-30). Therefore, accuracy,
specificity, and interference by nonesterified fatty acids have
been studied for three precipitants (obtained by hepann,
dextran sulfate, or polyvinyl sulfate precipitation). At normal
concentrations of LDL, precipitation is incomplete, whereas it
is nearly quantitative at high concentrations of LDL. The
polyvinyl sulfate reagent markedly responds to variations in
the amount of non-LDL protein present in the precipitation
mixture. In the dextran sulfate and the polyvinyl sulfate
method, but not in the heparin method, the percentages of
LDL precipitated notably increase as the concentration of the
polyanion compound is decreased. In either assay, very-low-
density lipoproteins, but not high-density lipoproteins, are
significantly coprecipitated (dextran sulfate 28%, polyvinyl
sulfate and heparin 66%) in a concentration-independent
fashion. increased concentrations of nonesterified fatty acids
markedly interfere with the dextran sulfate and polyvinyl
sulfate assay, but do not much affect results with the heparin
reagent.
Additional Keyphrases: intermethod comparison cholesterol
analytical error
Hypercholesterolemia represents one of the primary risk
factors for the premature development of atherosclerosis.
Whereas increased concentrations of low-density lipopro-
teins (LDL) confer a high cardiovascular risk, high-density
lipoproteins (HDL) are thought to exert protective effects
(1_3).2 Hence, individual risk proffles should include as-
says for HDL and LDL. A common approach to the quan-
tification of lipoprotein classes has been the measurement
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of HDL-C after precipitation of apolipoprotein (ape) B-con-
taining lipoproteins (4-7) and subsequent calculation of
LDL-C according to Friedewald et al. (4). In the meantime,
methods aimed at the selective precipitation and direct
quantification of LDL-C have been designed and are com-
mercially available (8-10).
Starting from our recent observation that concentrations
of LDL-C after precipitation with polyanion compounds are
lower than those obtained with a combined ultracentrifu-
gation-precipitation procedure (11), we have evaluated the
accuracies and specificities for LDL-C of three assays (8-
10) based on precipitation of LDL with either heparin,
dextran sulfate (DS), or polyvinyl sulfate (PVS).
Materials and Methods
Apparatus. For preparative ultracentrifugation we used
a Model L 8-70 (Beckman Instruments, Fullerton, CA) or a
Model TGA 75 (Kontron AG, Analytical Division, Zurich,
Switzerland) ultracentrifuge with fixed-angle rotors (Kon-
tron types TFF 50.38 and TVF 45.6). Densities were mon-
itored with a DMA 55 digital precision density meter (A.
Paar KG, Gras, Austria).
Reagents and other materials. Reagent kits for choles-
terol (Monotest CHOD-PAP) and triglycerides (GPO-PAP)
were purchased from Boehringer Mannheim, Mannheim,
F.R.G. The “NEFAC” test for the enzymatic determination
of nonesterified (free) fatty acids was obtained from Wako
Chemicals, Neuss, F.R.G. Celite 545 (analytical grade),
palmitic acid, stearic acid, and Tris were from Serva
Feinbiochemica, Heidelberg, F.R.G.; other chemicals were
from E. Merck, Darmstadt, F.R.G.
Blood collection. Blood samples from ostensibly healthy
donors, mostly women, ages 20 to 30 years, were obtained
by venipuncture after an overnight fast and drawn into
tubes containing K2EDTA at a final concentration of 1.5-2
g/L (Sarstedt, NUmbrecht, F.R.G.). Plasma was recovered
by centrifugation (1500 x g, 30 min) and stored at 4#{176}C.
Lipid analyses were completed within no more than five
days after blood collection.
Quantification of LDL-C. LDL-C was determined either
after precipitation with heparin (LDL-C), dextran sul-
fate (LDL-Cns), polyvinyl sulfate (LDL-C8), or by a
combined ultracentrifiigation and phosphotungstic acidl
MgC12 method (LDL-CUc,phT).
For LDL-C (8), we added 100 uL of sample to 1.0 mL
of precipitant (sodium citrate, 64 mmol/L, pH 5.04, and
heparin, 50 000 U/L), swirled, and incubated the mixture
